[1]
|
Waldman, A.D., Fritz, J.M. and Lenardo, M.J. (2020) A Guide to Cancer Immunotherapy: From T Cell Basic Science to Clinical Practice. Nature Reviews Immunology, 20, 651-668. https://doi.org/10.1038/s41577-020-0306-5
|
[2]
|
Puzanov, I., Diab, A., Abdallah, K., et al. (2017) Managing Tox-icities Associated With Immune Checkpoint Inhibitors: Consensus Recommendations from the Society for Immunother-apy of Cancer (SITC) Toxicity Management Working Group. Journal for ImmunoTherapy of Cancer, 5, Article No. 95. https://doi.org/10.1186/s40425-017-0300-z
|
[3]
|
Chang, L.-S., Barroso-Sousa, R., Tolaney, S.M., et al. (2019) Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. Endocrine Reviews, 40, 17-65. https://doi.org/10.1210/er.2018-00006
|
[4]
|
Akturk, H.K., Kahramangil, D., Sarwal, A., et al. (2019) Immune Checkpoint Inhibitor-Induced Type 1 Diabetes: A Systematic Review and Meta-Analysis. Diabetic Medicine, 36, 1075-1081. https://doi.org/10.1111/dme.14050
|
[5]
|
Liu, J., Shi, Y., Liu, X., et al. (2022) Clinical Characteristics and Outcomes of Immune Checkpoint Inhibitor-Induced Diabetes Mellitus. Translational Oncology, 24, Article ID: 101473. https://doi.org/10.1016/j.tranon.2022.101473
|
[6]
|
Clotman, K., Janssens, K., Specenier, P., et al. (2018) Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus. The Journal of Clinical Endocrinology and Me-tabolism, 103, 3144-3154.
https://doi.org/10.1210/jc.2018-00728
|
[7]
|
Dermani, F.K., Samadi, P., Rahmani, G., Kohlan, A.K. and Najafi, R. (2019) PD-1/PD-L1 Immune Checkpoint: Potential Target for Cancer Therapy. Journal of Cellular Physiology, 234, 1313-1325. https://doi.org/10.1002/jcp.27172
|
[8]
|
Mooradian, M.J. and Sullivan, R.J. (2017) Immunomodulatory Effects of Current Cancer Treatment and the Consequences for Follow-Up Immunotherapeutics. Future Oncology, 13, 1649-1663.
https://doi.org/10.2217/fon-2017-0117
|
[9]
|
D’Arrigo, P., Tufano, M., Rea, A., et al. (2020) Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules. Current Medicinal Chemis-try, 27, 2402-2448.
https://doi.org/10.2174/0929867325666181106114421
|
[10]
|
Elia, G., Ferrari, S.M., Galdiero, M.R., et al. (2020) New Insight in Endocrine-Related Adverse Events Associated to Immune Checkpoint Blockade. Best Practice & Re-search Clinical Endocrinology & Metabolism, 34, Article ID: 101370. https://doi.org/10.1016/j.beem.2019.101370
|
[11]
|
Castro, F., Cardoso, A.P., Gon Alves, R.M., Serre, K. and Oliveira, M.J. (2018) Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion. Frontiers in Im-munology, 9, Article 847.
https://doi.org/10.3389/fimmu.2018.00847
|
[12]
|
Wright, J.J., Powers, A.C. and Johnson, D.B. (2021) Endocrine Toxicities of Immune Checkpoint Inhibitors. Nature Reviews Endocrinology, 17, 389-399. https://doi.org/10.1038/s41574-021-00484-3
|
[13]
|
Zaied, A.A., Akturk, H.K., Joseph, R.W. and Lee, A.S. (2018) New-Onset Insulin-Dependent Diabetes due to Nivolumab. Endocrinology, Diabetes & Metabolism Case Reports, 2018, Article ID: 170174.
https://doi.org/10.1530/EDM-17-0174
|
[14]
|
中华医学会内分泌学分会免疫内分泌学组. 免疫检查点抑制剂引起的内分泌系统免疫相关不良反应专家共识(2020) [J]. 中华内分泌代谢杂志, 2021, 37(1): 1-16.
|
[15]
|
Ansari, M.J., Salama, A.D., Chitnis, T., et al. (2003) The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabe-tes in Nonobese Diabetic (NOD) Mice. The Journal of Experimental Medicine, 198, 63-69.
https://doi.org/10.1084/jem.20022125
|
[16]
|
Quandt, Z., Young, A. and Anderson, M. (2020) Immune Checkpoint Inhibitor Diabetes Mellitus: A Novel Form of Autoimmune Diabetes. Clinical and Experimental Immunology, 200, 131-140. https://doi.org/10.1111/cei.13424
|
[17]
|
Usui, Y., Udagawa, H., Matsumoto, S., et al. (2017) Association of Serum Anti-GAD Antibody and HLA Haplotypes with Type 1 Diabetes Mellitus Triggered by Nivolumab in Patients with Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 12, e41-e43. https://doi.org/10.1016/j.jtho.2016.12.015
|
[18]
|
Gauci, M.L., Laly, P., Vidal-Trecan, T., et al. (2017) Autoimmune Diabetes Induced by PD-1 Inhibitor-Retrospective Analysis and Pathogenesis: A Case Report and Literature Review. Cancer Immunology, Immunotherapy, 66, 1399-1410.
https://doi.org/10.1007/s00262-017-2033-8
|
[19]
|
Stamatouli, A.M., Quandt, Z., Perdigoto, A.L., et al. (2018) Col-lateral Damage: Insulin-Dependent Diabetes Induced with Checkpoint Inhibitors. Diabetes, 67, 1471-1480. https://doi.org/10.2337/dbi18-0002
|
[20]
|
Marchand, L., Thivolet, A., Dalle, S., et al. (2019) Diabetes Mellitus In-duced by PD-1 and PD-L1 Inhibitors: Description of Pancreatic Endocrine and Exocrine Phenotype. Acta Diabetologica, 56, 441-448.
https://doi.org/10.1007/s00592-018-1234-8
|
[21]
|
Mellati, M., Eaton, K.D., Brooks-Worrell, B.M., et al. (2015) An-ti-PD-1 and Anti-PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes. Diabetes Care, 38, e137-e138. https://doi.org/10.2337/dc15-0889
|
[22]
|
Hughes, J., Vudattu, N., Sznol, M., et al. (2015) Precipitation of Autoim-mune Diabetes with Anti-PD-1 Immunotherapy. Diabetes Care, 38, e55-e57. https://doi.org/10.2337/dc14-2349
|
[23]
|
Hansen, E., Sahasrabudhe, D. and Sievert, L. (2016) A Case Report of In-sulin-Dependent Diabetes as Immune-Related Toxicity of Pembrolizumab: Presentation, Management and Outcome. Cancer Immunology, Immunotherapy, 65, 765-767.
https://doi.org/10.1007/s00262-016-1835-4
|
[24]
|
Chae, Y.K., Chiec, L., Mohindra, N., et al. (2017) A Case of Pembrolizumab-Induced Type-1 Diabetes Mellitus and Discussion of Immune Checkpoint Inhibitor-Induced Type 1 Di-abetes. Cancer Immunology, Immunotherapy, 66, 25-32.
https://doi.org/10.1007/s00262-016-1913-7
|
[25]
|
Lowe, J.R., Perry, D.J., Salama, A.K., et al. (2016) Genetic Risk Analysis of a Patient with Fulminant Autoimmune Type 1 Diabetes Mellitus Secondary to Combination Ipilimumab and Nivolumab Immunotherapy. Journal for ImmunoTherapy of Cancer, 4, Article No. 89. https://doi.org/10.1186/s40425-016-0196-z
|
[26]
|
Hofmann, L., Forschner, A., Loquai, C., et al. (2016) Cutaneous, Gastrointestinal, Hepatic, Endocrine, and Renal Side-Effects of Anti-PD-1 Therapy. European Journal of Cancer, 60, 190-209.
https://doi.org/10.1016/j.ejca.2016.02.025
|
[27]
|
Alhusseini, M. and Samantray, J. (2017) Autoimmune Diabetes Superimposed on Type 2 Diabetes in a Patient Initiated on Immunotherapy for Lung Cancer. Diabetes & Metabolism, 43, 86-88. https://doi.org/10.1016/j.diabet.2016.05.007
|
[28]
|
Godwin, J.L., Jaggi, S., Sirisena, I., et al. (2017) Nivolumab-Induced Autoimmune Diabetes Mellitus Presenting as Diabetic Ketoacidosis in a Patient With Metastatic Lung Cancer. Journal for ImmunoTherapy of Cancer, 5, Article No. 40. https://doi.org/10.1186/s40425-017-0245-2
|
[29]
|
Alzenaidi, A.A., Dendy, J. and Rejjal, L. (2017) Autoimmune Diabetes Presented with Diabetic Ketoacidosis Induced by Immunotherapy in an Adult with Melanoma. The Journal of the Louisiana State Medical Society, 169, 49.
|
[30]
|
Leonardi, G.C., Oxnard, G.R., Haas, A., et al. (2017) Diabetic Ke-toacidosis as an Immune-Related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer. Journal of Im-munotherapy, 40, 249-251.
https://doi.org/10.1097/CJI.0000000000000173
|
[31]
|
Kollipara, R., Schneider, B., Radovich, M., Babu, S. and Kiel, P.J. (2017) Exceptional Response with Immunotherapy in a Patient with Anaplastic Thyroid Cancer. Oncologist, 22, 1149-1151.
https://doi.org/10.1634/theoncologist.2017-0096
|
[32]
|
Kapke, J,. Shaheen, Z., Kilari, D., Knudson, P. and Wong, S. (2017) Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of the Literature, and Optimal Management. Case Reports in Oncology, 10, 897-909.
https://doi.org/10.1159/000480634
|
[33]
|
Araújo, M., Ligeiro, D., Costa, L., et al. (2017) A Case of Fulminant Type 1 Diabetes Following Anti-PD1 Immunotherapy in a Genetically Susceptible Patient. Immunotherapy, 9, 531-535. https://doi.org/10.2217/imt-2017-0020
|
[34]
|
De Filette, J.M.K., Pen, J.J., Decoster, L., et al. (2019) Immune Checkpoint Inhibitors and Type 1 Diabetes Mellitus: A Case Report and Systematic Review. European Journal of Endo-crinology, 181, 363-374.
https://doi.org/10.1530/EJE-19-0291
|
[35]
|
Gaudy, C., Clévy, C., Monestier, S., et al. (2015) Anti-PD1 Pembroli-zumab Can Induce Exceptional Fulminant Type 1 Diabetes. Diabetes Care, 38, e182-e183. https://doi.org/10.2337/dc15-1331
|
[36]
|
Thoreau, B., Gouaillier-Vulcain, F., Machet, L., et al. (2017) Acute Lower Limb Ischaemia and Diabetes in a Patient Treated with Anti-PD1 Monoclonal Antibody for Metastatic Melanoma. Acta Dermato-Venereologica, 97, 408-409.
https://doi.org/10.2340/00015555-2504
|
[37]
|
Miyoshi, Y., Ogawa, O. and Oyama, Y. (2016) Nivolumab, an An-ti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes. The Tohoku Journal of Experimental Medi-cine, 239, 155-158.
https://doi.org/10.1620/tjem.239.155
|
[38]
|
Okamoto, M., Okamoto, M., Gotoh, K., et al. (2016) Fulminant Type 1 Diabetes Mellitus with Anti-Programmed Cell Death-1 Therapy. Journal of Diabetes Investigation, 7, 915-918. https://doi.org/10.1111/jdi.12531
|
[39]
|
Aleksova, J., Lau, P.K., Soldatos, G., et al. (2016) Glucocorticoids Did Not Reverse Type 1 Diabetes Mellitus Secondary to Pembrolizumab in a Patient With Metastatic Melanoma. BMJ Case Re-ports, 2016, Article ID: bcr2016217454.
https://doi.org/10.1136/bcr-2016-217454
|
[40]
|
Shah, M., Maxfield, L., Feroz, R. and Donohue, K. (2016) Rapid Development of Type 1 Diabetes Mellitus after Initiation of Anti-PD-1 Therapy. International Journal of Cancer and Clinical Research, 3, Article No. 066.
https://doi.org/10.23937/2378-3419/3/4/1066
|
[41]
|
Farrell, C.M., Casasola, R., Pearson, E.Z. and Schofield, C. (2017) Acute Onset Type1 Diabetes Precipitated by Pembrolizumab, an Anti-PD-1 Monoclonal Antibody Used as a Treatment for Melanoma. Diabetic Medicine, 34, 95.
|
[42]
|
Ishikawa, K., Shono-Saito, T., Yamate, T., et al. (2017) A Case of Fulminant Type 1 Diabetes Mellitus, with a Precipitous Decrease in Pancreatic Volume, Induced by Nivolumab for Malignant Melanoma: Analysis of HLA and CTLA-4 Polymorphisms. European Journal of Dermatology, 27, 184-185. https://doi.org/10.1684/ejd.2016.2923
|
[43]
|
曾海銮, 李晓牧, 高鑫. 一例PD-1抑制剂导致1型糖尿病病例报道及文献复习[J]. 中华内分泌代谢杂志, 2019, 35(7): 559-563.
|
[44]
|
程思远, 王正航, 鲁智豪, 沈琳. 抗PD-1/PD-L1治疗食管鳞癌诱发的1型糖尿病:个案报道及文献回顾[J]. 肿瘤综合治疗电子杂志, 2018, 4(1): 69-76.
|
[45]
|
Hickmott, L., De La Peña, H., Turner, H., et al. (2017) Anti-PD-L1 Atezolizumab-Induced Autoimmune Diabetes: A Case Report and Review of the Literature. Targeted Oncology, 12, 235-241.
https://doi.org/10.1007/s11523-017-0480-y
|
[46]
|
谷志远, 李薇, 杨涛, 等. 程序性死亡蛋白1抗体治疗后暴发性1型糖尿病一例[J]. 中华糖尿病杂志, 2020, 12(5): 328-332.
|
[47]
|
王妍, 罗晓红, 杨玲, 等. 应用程序性死亡受体1抑制剂后高血糖症二例报道及文献复习[J]. 中华糖尿病杂志, 2021, 13(1): 87-90.
|
[48]
|
何韬, 张祥波, 费云霞, 等. 抗PD-1治疗晚期肝恶性肿瘤诱发1型糖尿病1例[J]. 中华肝脏病杂志, 2020, 28(6): 518-520.
|
[49]
|
Li, S., Zhang, Y., Sun, Z., Hu, J. and Fang, C. (2018) Anti-PD-1 Pembrolizumab Induced Autoimmune Diabetes in Chinese Patient: A Case Report. Medicine, 97, e12907. https://doi.org/10.1097/MD.0000000000012907
|
[50]
|
Wu, L. and Li, B. (2021) A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma. Diabetes, Metabolic Syndrome and Obesity, 14, 753-757.
https://doi.org/10.2147/DMSO.S297709
|